Goldman Sachs Raises Price Target on Twist Bioscience to $55 From $45, Maintains Buy Rating
Goldman Sachs Maintains Buy on Twist Bioscience, Raises Price Target to $55
Twist Bioscience Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), HilleVax, Inc (HLVX) and Schrodinger (SDGR)
RBC Cuts Price Target on Beam Therapeutics to $27 From $35, Keeps Sector Perform, Speculative Risk
Jefferies Initiates Recursion Pharmaceuticals at Hold With $8 Price Target
Schrodinger Analyst Ratings
Leerink Partners Initiates Coverage On Schrodinger With Outperform Rating, Announces Price Target of $29
Twist Bioscience Analyst Ratings
RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $26
Nurix Therapeutics Analyst Ratings
Canaccord Genuity Maintains Buy on Intellia Therapeutics, Maintains $73 Price Target
Intellia Therapeutics Analyst Ratings
Ionis Pharmaceuticals Analyst Ratings
Needham Reiterates Buy on CRISPR Therapeutics, Maintains $88 Price Target
CRISPR Therapeutics Analyst Ratings
Needham Reiterates Buy on Recursion Pharmaceuticals, Maintains $17 Price Target
Recursion Pharmaceuticals Analyst Ratings
Intellia Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Intellia Therapeutics, Maintains $120 Price Target